showed

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

CoinDesk’s Consensus 2023 Draws 15,000 Attendees from Around the Globe to Austin, Texas

Source Node:
Time Stamp: May 10, 2023 12:35 PM - Modified On: May 10, 2023 - Published By:
Source Cluster:
Republished By Plato

AUSTIN, Texas, May 10, 2023 — CoinDesk's annual event, Consensus 2023, concluded on April 28th, bringing together a diverse group of 15,000 attendees, including developers, investors, policymakers, and major brands, to tackle the most pressing challenges facing crypto and Web3 today. CoinDesk is celebrating its 10th anniversary this year and the 9th year of Consensus. As the world's largest and most influential gathering of the crypto, blockchain, and Web3 communities, Consensus 2023 was a call to action to collaborate, innovate and find solutions to drive the industry forward. “Amid a